Abeona Therapeutics (ABEO) EBITDA (2011 - 2026)

Abeona Therapeutics' EBITDA history runs 16 years deep, the most recent figure standing at -$23.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 16.76% year-over-year to -$23.0 million; the TTM figure through Mar 2026 stood at -$92.8 million (down 33.25% YoY), while the FY2025 annual figure was -$89.4 million, down 39.3% from the prior year.
• EBITDA for Q1 2026 stood at -$23.0 million, down from -$22.9 million in the prior quarter.
• The five-year high for EBITDA was -$8.0 million in Q2 2022, with the low at -$24.0 million in Q3 2025.
• The 5-year median for EBITDA is -$15.3 million (2024), against an average of -$16.2 million.
• The sharpest annual moves came in 2022 and 2024: EBITDA soared 72.27% in 2022, then slumped 69.26% in 2024.
• Abeona Therapeutics' EBITDA stood at -$12.9 million in 2022, then dropped by 2.11% to -$13.2 million in 2023, then dropped by 26.22% to -$16.7 million in 2024, then slumped by 37.42% to -$22.9 million in 2025, then decreased by 0.53% to -$23.0 million in 2026.
• Business Quant data shows ABEO's EBITDA at -$23.0 million in Q1 2026, -$22.9 million in Q4 2025, and -$24.0 million in Q3 2025.